AGM Statement
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your PRM notes
At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, will make the following statement:
Since the start of 2024, we have seen significant customer engagement and interest in proteomics services reflected by the considerable increase in customer contact and quotations provided, including the substantial contract win from a US biopharmaceutical company announced on 26 April 2024.
The Company is confident and well positioned to see the business return to growth in 2024, following the launch of single cell proteomics ("SCP"), the introduction of new next generation tags in the isobaric and isotopic field, and the opening of the new facility in the USA during 2023 to provide services locally.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.